Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Autoprobiotics in the treatment of patients with colorectal cancer in the early postoperative period

Version 1 : Received: 27 February 2024 / Approved: 28 February 2024 / Online: 28 February 2024 (08:05:17 CET)

How to cite: Ermolenko, E.I.; Baryshnikova, N.V.; Alekhina, G.; Zakharenko, A.; Ten, O.; Kashchenko, V.A.; Lavrenova, N.; Gushchina, O.; Ovchinnikov, T.; Morozova, A.; Ilina, A.; Karaseva, A.B.; Tsapieva, A.; Gladyshev, N.; Dmitriev, A.V.; Suvorov, A. Autoprobiotics in the treatment of patients with colorectal cancer in the early postoperative period. Preprints 2024, 2024021605. https://doi.org/10.20944/preprints202402.1605.v1 Ermolenko, E.I.; Baryshnikova, N.V.; Alekhina, G.; Zakharenko, A.; Ten, O.; Kashchenko, V.A.; Lavrenova, N.; Gushchina, O.; Ovchinnikov, T.; Morozova, A.; Ilina, A.; Karaseva, A.B.; Tsapieva, A.; Gladyshev, N.; Dmitriev, A.V.; Suvorov, A. Autoprobiotics in the treatment of patients with colorectal cancer in the early postoperative period. Preprints 2024, 2024021605. https://doi.org/10.20944/preprints202402.1605.v1

Abstract

Introduction: Despite great advances in the treatment of oncological diseases, the development of medical technologies to prevent or reduce complications of therapy, in particular, those associated with surgery and the introduction of antibiotics remains relevant. The aim of the study: to evaluate the effectiveness of the use of autoprobiotics based on indigenous non-pathogenic strains of Enterococcus faecium and Enterococcus hirae in the complex therapy of colorectal cancer (CRC) in the early postoperative period. Materials and methods: A total of 36 patients diagnosed with CRC were enrolled in the study. The study group (Group A) comprised 24 CRC patients who received autoprobiotic therapy in the early postoperative period, while the control group (Group C) included 12 CRC patients without autoprobiotic therapy.Prior to surgery and between days 14-16 post-surgery, comprehensive evaluations were conducted on all patients, encompassing the following: stool and gastroenterological complains analysis. examination of the gut microbiota (bacteriological study, quantitative polymerase chain reaction, metagenome analysis), analysis of interleukins in serum. Results: The use of autoprobiotics led to decrease dyspeptic complaints after surgery, was associated with absence of postoperative complications, did not cause side effects, led to a decrease in the level of pro-inflammatory cytokines (IL-6 and IL-18) in the blood serum. The use of autoprobiotics led to positive changes in the structure of escherichia and enterococci populations, the elimination of Parvomonas micra, Fusobacterium nucleatum, decrease in the quantitative content of Clostridium perfringens, Akkermansia muciniphila. Metagenomic analysis (16S rRNA) revealed an increase in alpha diversity. Conclusion: The administration of autoprobiotics in the postoperative period is highly effective and safe in the comprehensive treatment of colorectal cancer patients. Future studies will allow the discovery of additional fine mechanisms of autoprobiotic therapy and its impact on the digestive, immune, endocrine and neural systems.

Keywords

microbiome, autoprobiotics, Enterococcus spp., Parvomonas micra, alpha diversity, gut dysbiosis, interleukins

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.